Identification

Name
Deslanoside
Accession Number
DB01078  (APRD00909)
Type
Small Molecule
Groups
Approved
Description

Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. [PubChem]

Structure
Thumb
Synonyms
  • (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide
  • 3-[(O-beta-D-Glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide
  • Deacetyllanatoside C
  • Desacetyllanatoside C
  • Deslanosido
  • Deslanosidum
  • Glucodigoxin
International/Other Brands
Cedilanid-d
Categories
UNII
YGY317RK75
CAS number
17598-65-1
Weight
Average: 943.0791
Monoisotopic: 942.482430186
Chemical Formula
C47H74O19
InChI Key
OBATZBGFDSVCJD-LALPQLPRSA-N
InChI
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-11,16-dihydroxy-5-{[(2R,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-5-{[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES

Pharmacology

Indication

For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.

Structured Indications
Not Available
Pharmacodynamics

Deslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.

Mechanism of action

Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

TargetActionsOrganism
ASodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
Absorption

Little absorption from the gastrointestinal tract (40%).

Volume of distribution
Not Available
Protein binding

20%

Metabolism
Not Available
Route of elimination
Not Available
Half life

36 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
10-hydroxycamptothecinDeslanoside may decrease the cardiotoxic activities of 10-hydroxycamptothecin.Investigational
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDeslanoside may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosoureaDeslanoside may decrease the cardiotoxic activities of 2-chloroethyl-3-sarcosinamide-1-nitrosourea.Investigational
2-MethoxyestradiolDeslanoside may decrease the cardiotoxic activities of 2-Methoxyestradiol.Investigational
3-MethoxybenzamideDeslanoside may decrease the cardiotoxic activities of 3-Methoxybenzamide.Experimental
3,3'-diindolylmethaneDeslanoside may decrease the cardiotoxic activities of 3,3'-diindolylmethane.Investigational
3,4-Dihydroxybenzoic AcidDeslanoside may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.Experimental
6-O-benzylguanineDeslanoside may decrease the cardiotoxic activities of 6-O-benzylguanine.Investigational
7-HydroxystaurosporineDeslanoside may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.Experimental, Investigational
8-azaguanineDeslanoside may decrease the cardiotoxic activities of 8-azaguanine.Experimental
9-aminocamptothecinDeslanoside may decrease the cardiotoxic activities of 9-aminocamptothecin.Investigational
AbirateroneDeslanoside may decrease the cardiotoxic activities of Abiraterone.Approved
AcebutololAcebutolol may increase the bradycardic activities of Deslanoside.Approved
AclarubicinDeslanoside may decrease the cardiotoxic activities of Aclarubicin.Investigational
Acridine CarboxamideDeslanoside may decrease the cardiotoxic activities of Acridine Carboxamide.Investigational
ActeosideDeslanoside may decrease the cardiotoxic activities of Acteoside.Investigational
AfatinibDeslanoside may decrease the cardiotoxic activities of Afatinib.Approved
AfimoxifeneDeslanoside may decrease the cardiotoxic activities of Afimoxifene.Investigational
AfliberceptDeslanoside may decrease the cardiotoxic activities of Aflibercept.Approved
AlatrofloxacinDeslanoside may decrease the cardiotoxic activities of Alatrofloxacin.Withdrawn
AlbendazoleDeslanoside may decrease the cardiotoxic activities of Albendazole.Approved, Vet Approved
AlcuroniumAlcuronium may increase the arrhythmogenic activities of Deslanoside.Experimental
AldesleukinDeslanoside may decrease the cardiotoxic activities of Aldesleukin.Approved
AlectinibDeslanoside may decrease the cardiotoxic activities of Alectinib.Approved
AlemtuzumabDeslanoside may decrease the cardiotoxic activities of Alemtuzumab.Approved, Investigational
AlitretinoinDeslanoside may decrease the cardiotoxic activities of Alitretinoin.Approved, Investigational
AlprenololAlprenolol may increase the bradycardic activities of Deslanoside.Approved, Withdrawn
AltretamineDeslanoside may decrease the cardiotoxic activities of Altretamine.Approved
AlvocidibDeslanoside may decrease the cardiotoxic activities of Alvocidib.Experimental, Investigational
AmikacinThe serum concentration of Deslanoside can be decreased when it is combined with Amikacin.Approved, Vet Approved
AmilorideThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Amiloride.Approved
AminoglutethimideDeslanoside may decrease the cardiotoxic activities of Aminoglutethimide.Approved, Investigational
Aminolevulinic acidDeslanoside may decrease the cardiotoxic activities of Aminolevulinic acid.Approved
AmiodaroneThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.Approved, Investigational
AmodiaquineThe serum concentration of Deslanoside can be increased when it is combined with Amodiaquine.Approved, Investigational
AmonafideDeslanoside may decrease the cardiotoxic activities of Amonafide.Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside.Approved, Investigational
AmrubicinDeslanoside may decrease the cardiotoxic activities of Amrubicin.Approved, Investigational
AmsacrineDeslanoside may decrease the cardiotoxic activities of Amsacrine.Approved
AnagrelideDeslanoside may decrease the cardiotoxic activities of Anagrelide.Approved
AnastrozoleDeslanoside may decrease the cardiotoxic activities of Anastrozole.Approved, Investigational
AnecortaveDeslanoside may decrease the cardiotoxic activities of Anecortave.Investigational
annamycinDeslanoside may decrease the cardiotoxic activities of annamycin.Investigational
AP 12009Deslanoside may decrease the cardiotoxic activities of AP 12009.Investigational
AP24534Deslanoside may decrease the cardiotoxic activities of AP24534.Investigational
ApaziquoneDeslanoside may decrease the cardiotoxic activities of Apaziquone.Investigational
ApramycinThe serum concentration of Deslanoside can be decreased when it is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe serum concentration of Deslanoside can be decreased when it is combined with Arbekacin.Approved, Investigational
Arotinoid acidDeslanoside may decrease the cardiotoxic activities of Arotinoid acid.Experimental
ArotinololArotinolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
Arsanilic acidDeslanoside may decrease the cardiotoxic activities of Arsanilic acid.Experimental, Vet Approved
Arsenic trioxideDeslanoside may decrease the cardiotoxic activities of Arsenic trioxide.Approved, Investigational
AsparaginaseDeslanoside may decrease the cardiotoxic activities of Asparaginase.Approved
AtenololAtenolol may increase the bradycardic activities of Deslanoside.Approved
AtezolizumabDeslanoside may decrease the cardiotoxic activities of Atezolizumab.Approved
AtracuriumAtracurium may increase the arrhythmogenic activities of Deslanoside.Experimental, Investigational
Atracurium besylateAtracurium besylate may increase the arrhythmogenic activities of Deslanoside.Approved
AxitinibDeslanoside may decrease the cardiotoxic activities of Axitinib.Approved, Investigational
AzacitidineDeslanoside may decrease the cardiotoxic activities of Azacitidine.Approved, Investigational
AzathioprineDeslanoside may decrease the cardiotoxic activities of Azathioprine.Approved
Azelaic AcidDeslanoside may decrease the cardiotoxic activities of Azelaic Acid.Approved
AzithromycinThe serum concentration of Deslanoside can be increased when it is combined with Azithromycin.Approved
BalsalazideThe serum concentration of Deslanoside can be decreased when it is combined with Balsalazide.Approved, Investigational
BatimastatDeslanoside may decrease the cardiotoxic activities of Batimastat.Experimental
BefunololBefunolol may increase the bradycardic activities of Deslanoside.Experimental
BekanamycinThe serum concentration of Deslanoside can be decreased when it is combined with Bekanamycin.Experimental
BelinostatDeslanoside may decrease the cardiotoxic activities of Belinostat.Approved, Investigational
BelotecanDeslanoside may decrease the cardiotoxic activities of Belotecan.Investigational
BendamustineDeslanoside may decrease the cardiotoxic activities of Bendamustine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Deslanoside.Approved
BesifloxacinDeslanoside may decrease the cardiotoxic activities of Besifloxacin.Approved
BetaxololBetaxolol may increase the bradycardic activities of Deslanoside.Approved
BevacizumabDeslanoside may decrease the cardiotoxic activities of Bevacizumab.Approved, Investigational
BevantololBevantolol may increase the bradycardic activities of Deslanoside.Approved
BexaroteneDeslanoside may decrease the cardiotoxic activities of Bexarotene.Approved, Investigational
BicalutamideDeslanoside may decrease the cardiotoxic activities of Bicalutamide.Approved
BinetrakinDeslanoside may decrease the cardiotoxic activities of Binetrakin.Investigational
BisoprololBisoprolol may increase the bradycardic activities of Deslanoside.Approved
BizelesinDeslanoside may decrease the cardiotoxic activities of Bizelesin.Investigational
BleomycinDeslanoside may decrease the cardiotoxic activities of Bleomycin.Approved
BlinatumomabDeslanoside may decrease the cardiotoxic activities of Blinatumomab.Approved
BopindololBopindolol may increase the bradycardic activities of Deslanoside.Approved
BortezomibDeslanoside may decrease the cardiotoxic activities of Bortezomib.Approved, Investigational
BosutinibDeslanoside may decrease the cardiotoxic activities of Bosutinib.Approved
Brentuximab vedotinDeslanoside may decrease the cardiotoxic activities of Brentuximab vedotin.Approved
BroxuridineDeslanoside may decrease the cardiotoxic activities of Broxuridine.Investigational
Bryostatin 1Deslanoside may decrease the cardiotoxic activities of Bryostatin 1.Investigational
BSI-201Deslanoside may decrease the cardiotoxic activities of BSI-201.Investigational
BucindololBucindolol may increase the bradycardic activities of Deslanoside.Investigational
BufuralolBufuralol may increase the bradycardic activities of Deslanoside.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Deslanoside.Approved
BupranololBupranolol may increase the bradycardic activities of Deslanoside.Approved
BuserelinDeslanoside may decrease the cardiotoxic activities of Buserelin.Approved
BusulfanDeslanoside may decrease the cardiotoxic activities of Busulfan.Approved, Investigational
Buthionine SulfoximineDeslanoside may decrease the cardiotoxic activities of Buthionine Sulfoximine.Investigational
CabazitaxelDeslanoside may decrease the cardiotoxic activities of Cabazitaxel.Approved
CabergolineDeslanoside may decrease the cardiotoxic activities of Cabergoline.Approved
CabozantinibDeslanoside may decrease the cardiotoxic activities of Cabozantinib.Approved
CalcidiolCalcidiol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
CalcipotriolDeslanoside may decrease the cardiotoxic activities of Calcipotriol.Approved
Calcium AcetateCalcium Acetate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium CarbonateCalcium Carbonate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium ChlorideCalcium Chloride may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium CitrateCalcium Citrate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium glubionateCalcium glubionate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium GluceptateCalcium Gluceptate may increase the arrhythmogenic activities of Deslanoside.Approved
Calcium gluconateCalcium gluconate may increase the arrhythmogenic activities of Deslanoside.Approved, Vet Approved
Calcium lactateCalcium lactate may increase the arrhythmogenic activities of Deslanoside.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate may increase the arrhythmogenic activities of Deslanoside.Experimental
Calcium laevulateCalcium laevulate may increase the arrhythmogenic activities of Deslanoside.Experimental
Calcium pangamateCalcium pangamate may increase the arrhythmogenic activities of Deslanoside.Experimental
Calcium PhosphateCalcium Phosphate may increase the arrhythmogenic activities of Deslanoside.Approved
CamptothecinDeslanoside may decrease the cardiotoxic activities of Camptothecin.Experimental
CanertinibDeslanoside may decrease the cardiotoxic activities of Canertinib.Investigational
CapecitabineDeslanoside may decrease the cardiotoxic activities of Capecitabine.Approved, Investigational
CarbimazoleThe serum concentration of Deslanoside can be increased when it is combined with Carbimazole.Approved, Investigational
CarbomycinThe serum concentration of Deslanoside can be increased when it is combined with Carbomycin.Vet Approved
CarboplatinDeslanoside may decrease the cardiotoxic activities of Carboplatin.Approved
CarboquoneDeslanoside may decrease the cardiotoxic activities of Carboquone.Experimental
CarboxyamidotriazoleDeslanoside may decrease the cardiotoxic activities of Carboxyamidotriazole.Investigational
CarfilzomibDeslanoside may decrease the cardiotoxic activities of Carfilzomib.Approved
CarmofurDeslanoside may decrease the cardiotoxic activities of Carmofur.Withdrawn
CarmustineDeslanoside may decrease the cardiotoxic activities of Carmustine.Approved
CarteololCarteolol may increase the bradycardic activities of Deslanoside.Approved
CarvedilolCarvedilol may increase the bradycardic activities of Deslanoside.Approved, Investigational
CaseinCasein may increase the arrhythmogenic activities of Deslanoside.Approved
CatumaxomabDeslanoside may decrease the cardiotoxic activities of Catumaxomab.Approved, Investigational
CediranibDeslanoside may decrease the cardiotoxic activities of Cediranib.Investigational
CeliprololCeliprolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
CeritinibDeslanoside may decrease the cardiotoxic activities of Ceritinib.Approved
CetuximabDeslanoside may decrease the cardiotoxic activities of Cetuximab.Approved
ChlorambucilDeslanoside may decrease the cardiotoxic activities of Chlorambucil.Approved
ChloroquineThe serum concentration of Deslanoside can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.Approved, Vet Approved
ChlorotrianiseneDeslanoside may decrease the cardiotoxic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Deslanoside.Approved
CholesterolDeslanoside may decrease the cardiotoxic activities of Cholesterol.Experimental, Investigational
CholestyramineCholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinDeslanoside may decrease the cardiotoxic activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinDeslanoside may decrease the cardiotoxic activities of Ciprofloxacin.Approved, Investigational
CisatracuriumCisatracurium may increase the arrhythmogenic activities of Deslanoside.Approved, Experimental
Cisatracurium besylateCisatracurium besylate may increase the arrhythmogenic activities of Deslanoside.Approved
CisplatinDeslanoside may decrease the cardiotoxic activities of Cisplatin.Approved
CladribineDeslanoside may decrease the cardiotoxic activities of Cladribine.Approved, Investigational
ClarithromycinThe serum concentration of Deslanoside can be increased when it is combined with Clarithromycin.Approved
ClofarabineDeslanoside may decrease the cardiotoxic activities of Clofarabine.Approved, Investigational
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
CloranololCloranolol may increase the bradycardic activities of Deslanoside.Experimental
CobimetinibDeslanoside may decrease the cardiotoxic activities of Cobimetinib.Approved
ColchicineDeslanoside may decrease the cardiotoxic activities of Colchicine.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CombretastatinDeslanoside may decrease the cardiotoxic activities of Combretastatin.Investigational
CordycepinDeslanoside may decrease the cardiotoxic activities of Cordycepin.Investigational
Coumermycin A1Deslanoside may decrease the cardiotoxic activities of Coumermycin A1.Experimental
CrenolanibDeslanoside may decrease the cardiotoxic activities of Crenolanib.Investigational
CrizotinibDeslanoside may decrease the cardiotoxic activities of Crizotinib.Approved
CurcuminDeslanoside may decrease the cardiotoxic activities of Curcumin.Investigational
CyclopenthiazideThe risk or severity of adverse effects can be increased when Cyclopenthiazide is combined with Deslanoside.Experimental
CyclophosphamideDeslanoside may decrease the cardiotoxic activities of Cyclophosphamide.Approved, Investigational
Cyproterone acetateDeslanoside may decrease the cardiotoxic activities of Cyproterone acetate.Approved, Investigational
CytarabineDeslanoside may decrease the cardiotoxic activities of Cytarabine.Approved, Investigational
DabrafenibDeslanoside may decrease the cardiotoxic activities of Dabrafenib.Approved
DacarbazineDeslanoside may decrease the cardiotoxic activities of Dacarbazine.Approved, Investigational
DactinomycinDeslanoside may decrease the cardiotoxic activities of Dactinomycin.Approved
DaratumumabDeslanoside may decrease the cardiotoxic activities of Daratumumab.Approved
DasatinibDeslanoside may decrease the cardiotoxic activities of Dasatinib.Approved, Investigational
DaunorubicinDeslanoside may decrease the cardiotoxic activities of Daunorubicin.Approved
DecamethoniumDecamethonium may increase the arrhythmogenic activities of Deslanoside.Approved
DecitabineDeslanoside may decrease the cardiotoxic activities of Decitabine.Approved, Investigational
DegarelixDeslanoside may decrease the cardiotoxic activities of Degarelix.Approved
DemecolcineDeslanoside may decrease the cardiotoxic activities of Demecolcine.Experimental
Denileukin diftitoxDeslanoside may decrease the cardiotoxic activities of Denileukin diftitox.Approved, Investigational
DeoxyspergualinDeslanoside may decrease the cardiotoxic activities of Deoxyspergualin.Investigational
DexamethasoneDeslanoside may decrease the cardiotoxic activities of Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneDeslanoside may decrease the cardiotoxic activities of Dexrazoxane.Approved, Withdrawn
DianhydrogalactitolDeslanoside may decrease the cardiotoxic activities of Dianhydrogalactitol.Investigational
DibekacinThe serum concentration of Deslanoside can be decreased when it is combined with Dibekacin.Experimental
DidoxDeslanoside may decrease the cardiotoxic activities of Didox.Investigational
DienogestDeslanoside may decrease the cardiotoxic activities of Dienogest.Approved
diethylnorspermineDeslanoside may decrease the cardiotoxic activities of diethylnorspermine.Investigational
DiethylstilbestrolDeslanoside may decrease the cardiotoxic activities of Diethylstilbestrol.Approved, Investigational
DihydrostreptomycinThe serum concentration of Deslanoside can be decreased when it is combined with Dihydrostreptomycin.Investigational, Vet Approved
DihydrotachysterolDihydrotachysterol may increase the arrhythmogenic activities of Deslanoside.Approved
DiltiazemDiltiazem may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DinutuximabDeslanoside may decrease the cardiotoxic activities of Dinutuximab.Approved
DocetaxelDeslanoside may decrease the cardiotoxic activities of Docetaxel.Approved, Investigational
Dolastatin 10Deslanoside may decrease the cardiotoxic activities of Dolastatin 10.Investigational
Domoic AcidDomoic Acid may increase the arrhythmogenic activities of Deslanoside.Experimental
Doxacurium chlorideDoxacurium chloride may increase the arrhythmogenic activities of Deslanoside.Approved
DoxercalciferolDoxercalciferol may increase the arrhythmogenic activities of Deslanoside.Approved
DoxifluridineDeslanoside may decrease the cardiotoxic activities of Doxifluridine.Investigational
DoxorubicinDeslanoside may decrease the cardiotoxic activities of Doxorubicin.Approved, Investigational
DuligotuzumabDeslanoside may decrease the cardiotoxic activities of Duligotuzumab.Investigational
EcabetDeslanoside may decrease the cardiotoxic activities of Ecabet.Approved, Investigational
EdrecolomabDeslanoside may decrease the cardiotoxic activities of Edrecolomab.Experimental, Investigational
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
EfaproxiralDeslanoside may decrease the cardiotoxic activities of Efaproxiral.Investigational
EfatutazoneDeslanoside may decrease the cardiotoxic activities of Efatutazone.Investigational
EflornithineDeslanoside may decrease the cardiotoxic activities of Eflornithine.Approved, Withdrawn
EG009Deslanoside may decrease the cardiotoxic activities of EG009.Investigational
ElotuzumabDeslanoside may decrease the cardiotoxic activities of Elotuzumab.Approved
ElsamitrucinDeslanoside may decrease the cardiotoxic activities of Elsamitrucin.Investigational
EndostatinDeslanoside may decrease the cardiotoxic activities of Endostatin.Investigational
EnoxacinDeslanoside may decrease the cardiotoxic activities of Enoxacin.Approved, Investigational
EnrofloxacinDeslanoside may decrease the cardiotoxic activities of Enrofloxacin.Vet Approved
EntinostatDeslanoside may decrease the cardiotoxic activities of Entinostat.Investigational
EnzalutamideDeslanoside may decrease the cardiotoxic activities of Enzalutamide.Approved
EpanololEpanolol may increase the bradycardic activities of Deslanoside.Experimental
Epigallocatechin GallateDeslanoside may decrease the cardiotoxic activities of Epigallocatechin Gallate.Investigational
EpirubicinDeslanoside may decrease the cardiotoxic activities of Epirubicin.Approved
EplerenoneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Eplerenone.Approved
EpofolateDeslanoside may decrease the cardiotoxic activities of Epofolate.Investigational
ErgocalciferolErgocalciferol may increase the arrhythmogenic activities of Deslanoside.Approved, Nutraceutical
EribulinDeslanoside may decrease the cardiotoxic activities of Eribulin.Approved, Investigational
ErlotinibDeslanoside may decrease the cardiotoxic activities of Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Deslanoside can be increased when it is combined with Erythromycin.Approved, Vet Approved
EsmololEsmolol may increase the bradycardic activities of Deslanoside.Approved
EstramustineDeslanoside may decrease the cardiotoxic activities of Estramustine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.Approved
EtanidazoleDeslanoside may decrease the cardiotoxic activities of Etanidazole.Investigational
Ethiodized oilDeslanoside may decrease the cardiotoxic activities of Ethiodized oil.Approved
Ethyl carbamateDeslanoside may decrease the cardiotoxic activities of Ethyl carbamate.Withdrawn
EtoglucidDeslanoside may decrease the cardiotoxic activities of Etoglucid.Experimental
EtoposideDeslanoside may decrease the cardiotoxic activities of Etoposide.Approved
EverolimusDeslanoside may decrease the cardiotoxic activities of Everolimus.Approved
ExatecanDeslanoside may decrease the cardiotoxic activities of Exatecan.Investigational
ExemestaneDeslanoside may decrease the cardiotoxic activities of Exemestane.Approved, Investigational
exisulindDeslanoside may decrease the cardiotoxic activities of exisulind.Investigational
FenretinideDeslanoside may decrease the cardiotoxic activities of Fenretinide.Investigational
FiacitabineDeslanoside may decrease the cardiotoxic activities of Fiacitabine.Investigational
FleroxacinDeslanoside may decrease the cardiotoxic activities of Fleroxacin.Approved
FloxuridineDeslanoside may decrease the cardiotoxic activities of Floxuridine.Approved
FludarabineDeslanoside may decrease the cardiotoxic activities of Fludarabine.Approved
FlumequineDeslanoside may decrease the cardiotoxic activities of Flumequine.Withdrawn
FluorouracilDeslanoside may decrease the cardiotoxic activities of Fluorouracil.Approved
FlutamideDeslanoside may decrease the cardiotoxic activities of Flutamide.Approved
FormestaneDeslanoside may decrease the cardiotoxic activities of Formestane.Approved, Investigational, Withdrawn
FormycinDeslanoside may decrease the cardiotoxic activities of Formycin.Experimental
FosbretabulinDeslanoside may decrease the cardiotoxic activities of Fosbretabulin.Investigational
FotemustineDeslanoside may decrease the cardiotoxic activities of Fotemustine.Experimental, Investigational
FramycetinThe serum concentration of Deslanoside can be decreased when it is combined with Framycetin.Approved
FulvestrantDeslanoside may decrease the cardiotoxic activities of Fulvestrant.Approved, Investigational
FumagillinDeslanoside may decrease the cardiotoxic activities of Fumagillin.Experimental
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Deslanoside.Approved, Vet Approved
GallamineGallamine may increase the arrhythmogenic activities of Deslanoside.Experimental
Gallamine TriethiodideGallamine Triethiodide may increase the arrhythmogenic activities of Deslanoside.Approved
Gallium nitrateDeslanoside may decrease the cardiotoxic activities of Gallium nitrate.Approved, Investigational
GarenoxacinDeslanoside may decrease the cardiotoxic activities of Garenoxacin.Investigational
GatifloxacinDeslanoside may decrease the cardiotoxic activities of Gatifloxacin.Approved, Investigational
GefitinibDeslanoside may decrease the cardiotoxic activities of Gefitinib.Approved, Investigational
GeldanamycinDeslanoside may decrease the cardiotoxic activities of Geldanamycin.Experimental, Investigational
GemcitabineDeslanoside may decrease the cardiotoxic activities of Gemcitabine.Approved
GemifloxacinDeslanoside may decrease the cardiotoxic activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinDeslanoside may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.Approved
GeneticinThe serum concentration of Deslanoside can be decreased when it is combined with Geneticin.Experimental
GenisteinDeslanoside may decrease the cardiotoxic activities of Genistein.Investigational
GentamicinThe serum concentration of Deslanoside can be decreased when it is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of Deslanoside can be decreased when it is combined with GENTAMICIN C1A.Experimental
Ginsenoside CDeslanoside may decrease the cardiotoxic activities of Ginsenoside C.Nutraceutical
GoserelinDeslanoside may decrease the cardiotoxic activities of Goserelin.Approved
GPX-150The serum concentration of Deslanoside can be decreased when it is combined with GPX-150.Investigational
GrepafloxacinDeslanoside may decrease the cardiotoxic activities of Grepafloxacin.Investigational, Withdrawn
GS 0573Deslanoside may decrease the cardiotoxic activities of GS 0573.Investigational
GusperimusDeslanoside may decrease the cardiotoxic activities of Gusperimus.Investigational
HadacidinDeslanoside may decrease the cardiotoxic activities of Hadacidin.Experimental
HalofuginoneDeslanoside may decrease the cardiotoxic activities of Halofuginone.Investigational, Vet Approved
HexestrolDeslanoside may decrease the cardiotoxic activities of Hexestrol.Withdrawn
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Deslanoside.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside.Approved, Investigational
HydroxychloroquineThe serum concentration of Deslanoside can be increased when it is combined with Hydroxychloroquine.Approved
Hydroxyprogesterone caproateDeslanoside may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.Approved
HydroxyureaDeslanoside may decrease the cardiotoxic activities of Hydroxyurea.Approved
Hygromycin BThe serum concentration of Deslanoside can be decreased when it is combined with Hygromycin B.Vet Approved
HypericinDeslanoside may decrease the cardiotoxic activities of Hypericin.Investigational
IbrutinibDeslanoside may decrease the cardiotoxic activities of Ibrutinib.Approved
IdarubicinDeslanoside may decrease the cardiotoxic activities of Idarubicin.Approved
IdelalisibDeslanoside may decrease the cardiotoxic activities of Idelalisib.Approved
IfosfamideDeslanoside may decrease the cardiotoxic activities of Ifosfamide.Approved
ImatinibDeslanoside may decrease the cardiotoxic activities of Imatinib.Approved
ImiquimodDeslanoside may decrease the cardiotoxic activities of Imiquimod.Approved, Investigational
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Deslanoside.Approved
IndenololIndenolol may increase the bradycardic activities of Deslanoside.Withdrawn
IndirubinDeslanoside may decrease the cardiotoxic activities of Indirubin.Investigational
Indole-3-carbinolDeslanoside may decrease the cardiotoxic activities of Indole-3-carbinol.Investigational
InfigratinibDeslanoside may decrease the cardiotoxic activities of Infigratinib.Investigational
IniparibDeslanoside may decrease the cardiotoxic activities of Iniparib.Experimental, Investigational
INNO-206The serum concentration of Deslanoside can be decreased when it is combined with INNO-206.Investigational
Interferon Alfa-2b, RecombinantDeslanoside may decrease the cardiotoxic activities of Interferon Alfa-2b, Recombinant.Approved
Interferon beta-1aDeslanoside may decrease the cardiotoxic activities of Interferon beta-1a.Approved, Investigational
IobenguaneDeslanoside may decrease the cardiotoxic activities of Iobenguane.Approved, Investigational
IpilimumabDeslanoside may decrease the cardiotoxic activities of Ipilimumab.Approved
IrinotecanDeslanoside may decrease the cardiotoxic activities of Irinotecan.Approved, Investigational
IrofulvenDeslanoside may decrease the cardiotoxic activities of Irofulven.Investigational
IrsogladineDeslanoside may decrease the cardiotoxic activities of Irsogladine.Investigational
IsepamicinThe serum concentration of Deslanoside can be decreased when it is combined with Isepamicin.Experimental
IsosorbideDeslanoside may decrease the cardiotoxic activities of Isosorbide.Approved, Investigational
ItraconazoleThe serum concentration of Deslanoside can be increased when it is combined with Itraconazole.Approved, Investigational
IxabepiloneDeslanoside may decrease the cardiotoxic activities of Ixabepilone.Approved, Investigational
IxazomibDeslanoside may decrease the cardiotoxic activities of Ixazomib.Approved
JosamycinThe serum concentration of Deslanoside can be increased when it is combined with Josamycin.Approved, Investigational
KanamycinThe serum concentration of Deslanoside can be decreased when it is combined with Kanamycin.Approved, Investigational, Vet Approved
KaolinThe serum concentration of Deslanoside can be decreased when it is combined with Kaolin.Approved
KitasamycinThe serum concentration of Deslanoside can be increased when it is combined with Kitasamycin.Experimental
KOS-1584Deslanoside may decrease the cardiotoxic activities of KOS-1584.Investigational
KRN-7000Deslanoside may decrease the cardiotoxic activities of KRN-7000.Investigational
L-alanosineDeslanoside may decrease the cardiotoxic activities of L-alanosine.Investigational
LabetalolLabetalol may increase the bradycardic activities of Deslanoside.Approved
LandiololLandiolol may increase the bradycardic activities of Deslanoside.Investigational
LanreotideDeslanoside may decrease the cardiotoxic activities of Lanreotide.Approved
LapatinibDeslanoside may decrease the cardiotoxic activities of Lapatinib.Approved, Investigational
LCL-161Deslanoside may decrease the cardiotoxic activities of LCL-161.Investigational
LeflunomideDeslanoside may decrease the cardiotoxic activities of Leflunomide.Approved, Investigational
LenalidomideDeslanoside may decrease the cardiotoxic activities of Lenalidomide.Approved
LentinanDeslanoside may decrease the cardiotoxic activities of Lentinan.Experimental, Investigational
LenvatinibDeslanoside may decrease the cardiotoxic activities of Lenvatinib.Approved
LetrozoleDeslanoside may decrease the cardiotoxic activities of Letrozole.Approved, Investigational
LeuprolideDeslanoside may decrease the cardiotoxic activities of Leuprolide.Approved, Investigational
LevobunololLevobunolol may increase the bradycardic activities of Deslanoside.Approved
LevofloxacinDeslanoside may decrease the cardiotoxic activities of Levofloxacin.Approved, Investigational
LiarozoleDeslanoside may decrease the cardiotoxic activities of Liarozole.Investigational
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Deslanoside.Approved
LomefloxacinDeslanoside may decrease the cardiotoxic activities of Lomefloxacin.Approved, Investigational
LometrexolDeslanoside may decrease the cardiotoxic activities of Lometrexol.Investigational
LomustineDeslanoside may decrease the cardiotoxic activities of Lomustine.Approved
LonidamineDeslanoside may decrease the cardiotoxic activities of Lonidamine.Approved, Investigational
LurtotecanDeslanoside may decrease the cardiotoxic activities of Lurtotecan.Investigational
LycopeneDeslanoside may decrease the cardiotoxic activities of Lycopene.Approved
MafosfamideDeslanoside may decrease the cardiotoxic activities of Mafosfamide.Investigational
MannosulfanDeslanoside may decrease the cardiotoxic activities of Mannosulfan.Experimental
MasitinibDeslanoside may decrease the cardiotoxic activities of Masitinib.Investigational, Vet Approved
MasoprocolDeslanoside may decrease the cardiotoxic activities of Masoprocol.Approved, Investigational
MaxacalcitolDeslanoside may decrease the cardiotoxic activities of Maxacalcitol.Approved, Investigational
MebendazoleDeslanoside may decrease the cardiotoxic activities of Mebendazole.Approved, Vet Approved
MechlorethamineDeslanoside may decrease the cardiotoxic activities of Mechlorethamine.Approved
MedrogestoneDeslanoside may decrease the cardiotoxic activities of Medrogestone.Approved
Medroxyprogesterone acetateDeslanoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateDeslanoside may decrease the cardiotoxic activities of Megestrol acetate.Approved, Vet Approved
MelphalanDeslanoside may decrease the cardiotoxic activities of Melphalan.Approved
MepindololMepindolol may increase the bradycardic activities of Deslanoside.Experimental
MequinolDeslanoside may decrease the cardiotoxic activities of Mequinol.Approved
MercaptopurineDeslanoside may decrease the cardiotoxic activities of Mercaptopurine.Approved
MerestinibDeslanoside may decrease the cardiotoxic activities of Merestinib.Investigational
MesalazineThe serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.Approved
MethimazoleThe serum concentration of Deslanoside can be increased when it is combined with Methimazole.Approved
MethotrexateDeslanoside may decrease the cardiotoxic activities of Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside.Approved
Methyl aminolevulinateDeslanoside may decrease the cardiotoxic activities of Methyl aminolevulinate.Approved
MethylprednisoloneDeslanoside may decrease the cardiotoxic activities of Methylprednisolone.Approved, Vet Approved
MethylselenocysteineDeslanoside may decrease the cardiotoxic activities of Methylselenocysteine.Investigational
MethyltestosteroneDeslanoside may decrease the cardiotoxic activities of Methyltestosterone.Approved
MethylthiouracilThe serum concentration of Deslanoside can be increased when it is combined with Methylthiouracil.Experimental
MetipranololMetipranolol may increase the bradycardic activities of Deslanoside.Approved
MetocurineMetocurine may increase the arrhythmogenic activities of Deslanoside.Approved
Metocurine IodideMetocurine Iodide may increase the arrhythmogenic activities of Deslanoside.Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.Approved
MetoprineDeslanoside may decrease the cardiotoxic activities of Metoprine.Experimental
MetoprololMetoprolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
MetrizamideThe serum concentration of Deslanoside can be decreased when it is combined with Metrizamide.Approved
MicronomicinThe serum concentration of Deslanoside can be decreased when it is combined with Micronomicin.Experimental
MidodrineDeslanoside may increase the bradycardic activities of Midodrine.Approved
MidostaurinDeslanoside may decrease the cardiotoxic activities of Midostaurin.Approved
MiltefosineDeslanoside may decrease the cardiotoxic activities of Miltefosine.Approved
MisonidazoleDeslanoside may decrease the cardiotoxic activities of Misonidazole.Investigational
MitobronitolDeslanoside may decrease the cardiotoxic activities of Mitobronitol.Experimental
MitoguazoneDeslanoside may decrease the cardiotoxic activities of Mitoguazone.Investigational
MitolactolDeslanoside may decrease the cardiotoxic activities of Mitolactol.Investigational
MitomycinDeslanoside may decrease the cardiotoxic activities of Mitomycin.Approved
MitotaneDeslanoside may decrease the cardiotoxic activities of Mitotane.Approved
MitoxantroneDeslanoside may decrease the cardiotoxic activities of Mitoxantrone.Approved, Investigational
MivacuriumMivacurium may increase the arrhythmogenic activities of Deslanoside.Approved
MizoribineDeslanoside may decrease the cardiotoxic activities of Mizoribine.Investigational
MLN576Deslanoside may decrease the cardiotoxic activities of MLN576.Investigational
MolgramostimDeslanoside may decrease the cardiotoxic activities of Molgramostim.Investigational
motexafin gadoliniumDeslanoside may decrease the cardiotoxic activities of motexafin gadolinium.Investigational
MoxifloxacinDeslanoside may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilDeslanoside may decrease the cardiotoxic activities of Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.Approved
NadifloxacinDeslanoside may decrease the cardiotoxic activities of Nadifloxacin.Investigational
NadololNadolol may increase the bradycardic activities of Deslanoside.Approved
Nalidixic AcidDeslanoside may decrease the cardiotoxic activities of Nalidixic Acid.Approved, Investigational
NamitecanDeslanoside may decrease the cardiotoxic activities of Namitecan.Investigational
NavitoclaxDeslanoside may decrease the cardiotoxic activities of Navitoclax.Investigational
NeamineThe serum concentration of Deslanoside can be decreased when it is combined with Neamine.Experimental
NebivololNebivolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
NebularineDeslanoside may decrease the cardiotoxic activities of Nebularine.Experimental
NecitumumabDeslanoside may decrease the cardiotoxic activities of Necitumumab.Approved
NedaplatinDeslanoside may decrease the cardiotoxic activities of Nedaplatin.Approved, Investigational
NelarabineDeslanoside may decrease the cardiotoxic activities of Nelarabine.Approved, Investigational
NeomycinThe serum concentration of Deslanoside can be decreased when it is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinNeosaxitoxin may increase the arrhythmogenic activities of Deslanoside.Investigational
NetilmicinThe serum concentration of Deslanoside can be decreased when it is combined with Netilmicin.Approved, Investigational
NiguldipineDeslanoside may decrease the cardiotoxic activities of Niguldipine.Experimental
NilotinibDeslanoside may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
NilutamideDeslanoside may decrease the cardiotoxic activities of Nilutamide.Approved
NimustineDeslanoside may decrease the cardiotoxic activities of Nimustine.Investigational
NintedanibDeslanoside may decrease the cardiotoxic activities of Nintedanib.Approved
NiraparibDeslanoside may decrease the cardiotoxic activities of Niraparib.Approved, Investigational
NivolumabDeslanoside may decrease the cardiotoxic activities of Nivolumab.Approved
nocodazoleDeslanoside may decrease the cardiotoxic activities of nocodazole.Experimental
NolatrexedDeslanoside may decrease the cardiotoxic activities of Nolatrexed.Investigational
NorfloxacinDeslanoside may decrease the cardiotoxic activities of Norfloxacin.Approved
ObinutuzumabDeslanoside may decrease the cardiotoxic activities of Obinutuzumab.Approved
OblimersenDeslanoside may decrease the cardiotoxic activities of Oblimersen.Experimental, Investigational
OBP-801Deslanoside may decrease the cardiotoxic activities of OBP-801.Investigational
OctreotideDeslanoside may decrease the cardiotoxic activities of Octreotide.Approved, Investigational
OfatumumabDeslanoside may decrease the cardiotoxic activities of Ofatumumab.Approved
OfloxacinDeslanoside may decrease the cardiotoxic activities of Ofloxacin.Approved
OglufanideDeslanoside may decrease the cardiotoxic activities of Oglufanide.Investigational
OlaparibDeslanoside may decrease the cardiotoxic activities of Olaparib.Approved
OleandomycinThe serum concentration of Deslanoside can be increased when it is combined with Oleandomycin.Vet Approved
OlsalazineThe serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.Approved
OltiprazDeslanoside may decrease the cardiotoxic activities of Oltipraz.Investigational
Omacetaxine mepesuccinateDeslanoside may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.Approved
OnapristoneDeslanoside may decrease the cardiotoxic activities of Onapristone.Investigational
OprelvekinDeslanoside may decrease the cardiotoxic activities of Oprelvekin.Approved, Investigational
OsimertinibDeslanoside may decrease the cardiotoxic activities of Osimertinib.Approved
OxaliplatinDeslanoside may decrease the cardiotoxic activities of Oxaliplatin.Approved, Investigational
Oxolinic acidDeslanoside may decrease the cardiotoxic activities of Oxolinic acid.Experimental
OxprenololOxprenolol may increase the bradycardic activities of Deslanoside.Approved
PaclitaxelDeslanoside may decrease the cardiotoxic activities of Paclitaxel.Approved, Vet Approved
Paclitaxel poliglumexDeslanoside may decrease the cardiotoxic activities of Paclitaxel poliglumex.Experimental, Investigational
PalbociclibDeslanoside may decrease the cardiotoxic activities of Palbociclib.Approved
PalifosfamideDeslanoside may decrease the cardiotoxic activities of Palifosfamide.Investigational
PamidronateDeslanoside may decrease the cardiotoxic activities of Pamidronate.Approved
PancuroniumPancuronium may increase the arrhythmogenic activities of Deslanoside.Approved
PanitumumabDeslanoside may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
PanobinostatDeslanoside may decrease the cardiotoxic activities of Panobinostat.Approved, Investigational
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Deslanoside.Approved, Investigational
ParicalcitolParicalcitol may increase the arrhythmogenic activities of Deslanoside.Approved, Investigational
ParomomycinThe serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.Approved, Investigational
PatupiloneDeslanoside may decrease the cardiotoxic activities of Patupilone.Experimental, Investigational
PazopanibDeslanoside may decrease the cardiotoxic activities of Pazopanib.Approved
PazufloxacinDeslanoside may decrease the cardiotoxic activities of Pazufloxacin.Investigational
PefloxacinDeslanoside may decrease the cardiotoxic activities of Pefloxacin.Approved
PegaspargaseDeslanoside may decrease the cardiotoxic activities of Pegaspargase.Approved, Investigational
PembrolizumabDeslanoside may decrease the cardiotoxic activities of Pembrolizumab.Approved
PemetrexedDeslanoside may decrease the cardiotoxic activities of Pemetrexed.Approved, Investigational
PenbutololPenbutolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
PenclomedineDeslanoside may decrease the cardiotoxic activities of Penclomedine.Investigational
PentostatinDeslanoside may decrease the cardiotoxic activities of Pentostatin.Approved, Investigational
PertuzumabDeslanoside may decrease the cardiotoxic activities of Pertuzumab.Approved
Phenethyl IsothiocyanateDeslanoside may decrease the cardiotoxic activities of Phenethyl Isothiocyanate.Investigational
Phenylacetic acidDeslanoside may decrease the cardiotoxic activities of Phenylacetic acid.Approved
Phenylbutyric acidDeslanoside may decrease the cardiotoxic activities of Phenylbutyric acid.Approved, Investigational
PindololPindolol may increase the bradycardic activities of Deslanoside.Approved
PinometostatDeslanoside may decrease the cardiotoxic activities of Pinometostat.Investigational
PipecuroniumPipecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
PipobromanDeslanoside may decrease the cardiotoxic activities of Pipobroman.Approved
PirarubicinDeslanoside may decrease the cardiotoxic activities of Pirarubicin.Investigational
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.Experimental
PirfenidoneDeslanoside may decrease the cardiotoxic activities of Pirfenidone.Approved, Investigational
PirlindoleDeslanoside may decrease the cardiotoxic activities of Pirlindole.Approved
PixantroneDeslanoside may decrease the cardiotoxic activities of Pixantrone.Approved, Investigational
Platelet Activating FactorPlatelet Activating Factor may increase the bradycardic activities of Deslanoside.Experimental
PlazomicinThe serum concentration of Deslanoside can be decreased when it is combined with Plazomicin.Investigational
PlevitrexedDeslanoside may decrease the cardiotoxic activities of Plevitrexed.Investigational
PlicamycinDeslanoside may decrease the cardiotoxic activities of Plicamycin.Approved, Investigational, Withdrawn
PodofiloxDeslanoside may decrease the cardiotoxic activities of Podofilox.Approved
PodophyllinDeslanoside may decrease the cardiotoxic activities of Podophyllin.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Deslanoside.Approved
PomalidomideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.Approved
PonatinibDeslanoside may decrease the cardiotoxic activities of Ponatinib.Approved
Porfimer sodiumDeslanoside may decrease the cardiotoxic activities of Porfimer sodium.Approved, Investigational
porfiromycinDeslanoside may decrease the cardiotoxic activities of porfiromycin.Investigational
Potassium IodideThe serum concentration of Deslanoside can be increased when it is combined with Potassium Iodide.Approved
PractololPractolol may increase the bradycardic activities of Deslanoside.Approved
PralatrexateDeslanoside may decrease the cardiotoxic activities of Pralatrexate.Approved
PrednimustineDeslanoside may decrease the cardiotoxic activities of Prednimustine.Investigational
PrednisoloneDeslanoside may decrease the cardiotoxic activities of Prednisolone.Approved, Vet Approved
PrednisoneDeslanoside may decrease the cardiotoxic activities of Prednisone.Approved, Vet Approved
PrimaquineThe serum concentration of Deslanoside can be increased when it is combined with Primaquine.Approved
ProcarbazineDeslanoside may decrease the cardiotoxic activities of Procarbazine.Approved
PropafenoneThe serum concentration of Deslanoside can be increased when it is combined with Propafenone.Approved
PropranololPropranolol may increase the bradycardic activities of Deslanoside.Approved, Investigational
PropylthiouracilThe serum concentration of Deslanoside can be increased when it is combined with Propylthiouracil.Approved
PrulifloxacinDeslanoside may decrease the cardiotoxic activities of Prulifloxacin.Investigational
PuromycinDeslanoside may decrease the cardiotoxic activities of Puromycin.Experimental
PyrantelPyrantel may increase the arrhythmogenic activities of Deslanoside.Approved, Vet Approved
PyrazoloacridineDeslanoside may decrease the cardiotoxic activities of Pyrazoloacridine.Investigational
QuinacrineDeslanoside may decrease the cardiotoxic activities of Quinacrine.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Deslanoside.Approved
QuinidineThe serum concentration of Deslanoside can be increased when it is combined with Quinidine.Approved
RabusertibDeslanoside may decrease the cardiotoxic activities of Rabusertib.Investigational
Radium Ra 223 DichlorideDeslanoside may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedDeslanoside may decrease the cardiotoxic activities of Raltitrexed.Approved, Investigational
RamucirumabDeslanoside may decrease the cardiotoxic activities of Ramucirumab.Approved, Investigational
RanibizumabDeslanoside may decrease the cardiotoxic activities of Ranibizumab.Approved
RanimustineDeslanoside may decrease the cardiotoxic activities of Ranimustine.Experimental
RanpirnaseDeslanoside may decrease the cardiotoxic activities of Ranpirnase.Investigational
RapacuroniumRapacuronium may increase the arrhythmogenic activities of Deslanoside.Withdrawn
RegorafenibDeslanoside may decrease the cardiotoxic activities of Regorafenib.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Deslanoside.Approved, Investigational
ResveratrolDeslanoside may decrease the cardiotoxic activities of Resveratrol.Approved, Experimental, Investigational
Rhodamine 6GDeslanoside may decrease the cardiotoxic activities of Rhodamine 6G.Experimental
RibostamycinThe serum concentration of Deslanoside can be decreased when it is combined with Ribostamycin.Approved, Investigational
RidaforolimusDeslanoside may decrease the cardiotoxic activities of Ridaforolimus.Investigational
RituximabDeslanoside may decrease the cardiotoxic activities of Rituximab.Approved
RocuroniumRocuronium may increase the arrhythmogenic activities of Deslanoside.Approved
RomidepsinDeslanoside may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
RoquinimexDeslanoside may decrease the cardiotoxic activities of Roquinimex.Investigational
RubitecanDeslanoside may decrease the cardiotoxic activities of Rubitecan.Investigational
RucaparibDeslanoside may decrease the cardiotoxic activities of Rucaparib.Approved, Investigational
RufloxacinDeslanoside may decrease the cardiotoxic activities of Rufloxacin.Experimental
RuxolitinibDeslanoside may decrease the cardiotoxic activities of Ruxolitinib.Approved
SabarubicinThe serum concentration of Deslanoside can be decreased when it is combined with Sabarubicin.Investigational
SalirasibDeslanoside may decrease the cardiotoxic activities of Salirasib.Investigational
SaracatinibDeslanoside may decrease the cardiotoxic activities of Saracatinib.Investigational
SatraplatinDeslanoside may decrease the cardiotoxic activities of Satraplatin.Investigational
SeliciclibDeslanoside may decrease the cardiotoxic activities of Seliciclib.Investigational
SemaxanibDeslanoside may decrease the cardiotoxic activities of Semaxanib.Investigational
SemustineDeslanoside may decrease the cardiotoxic activities of Semustine.Experimental, Investigational
SeocalcitolDeslanoside may decrease the cardiotoxic activities of Seocalcitol.Experimental, Investigational
SiltuximabDeslanoside may decrease the cardiotoxic activities of Siltuximab.Approved
SirolimusDeslanoside may decrease the cardiotoxic activities of Sirolimus.Approved, Investigational
SisomicinThe serum concentration of Deslanoside can be decreased when it is combined with Sisomicin.Investigational
SitafloxacinDeslanoside may decrease the cardiotoxic activities of Sitafloxacin.Experimental, Investigational
SizofiranDeslanoside may decrease the cardiotoxic activities of Sizofiran.Investigational
SoblidotinDeslanoside may decrease the cardiotoxic activities of Soblidotin.Investigational
SolithromycinThe serum concentration of Deslanoside can be increased when it is combined with Solithromycin.Investigational
SonidegibDeslanoside may decrease the cardiotoxic activities of Sonidegib.Approved, Investigational
SorafenibDeslanoside may decrease the cardiotoxic activities of Sorafenib.Approved, Investigational
SotalolSotalol may increase the bradycardic activities of Deslanoside.Approved
SP1049CThe serum concentration of Deslanoside can be decreased when it is combined with SP1049C.Investigational
SparfloxacinDeslanoside may decrease the cardiotoxic activities of Sparfloxacin.Approved, Investigational
Sparfosic acidDeslanoside may decrease the cardiotoxic activities of Sparfosic acid.Experimental
SparsomycinDeslanoside may decrease the cardiotoxic activities of Sparsomycin.Experimental
SpectinomycinThe serum concentration of Deslanoside can be decreased when it is combined with Spectinomycin.Approved, Investigational, Vet Approved
SpiramycinThe serum concentration of Deslanoside can be increased when it is combined with Spiramycin.Approved
SpironolactoneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone.Approved
squalamineDeslanoside may decrease the cardiotoxic activities of squalamine.Investigational
SRT501Deslanoside may decrease the cardiotoxic activities of SRT501.Investigational
StreptomycinThe serum concentration of Deslanoside can be decreased when it is combined with Streptomycin.Approved, Vet Approved
StreptozocinDeslanoside may decrease the cardiotoxic activities of Streptozocin.Approved
SuccinylcholineSuccinylcholine may increase the arrhythmogenic activities of Deslanoside.Approved
SulforaphaneDeslanoside may decrease the cardiotoxic activities of Sulforaphane.Investigational
SulindacDeslanoside may decrease the cardiotoxic activities of Sulindac.Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Deslanoside.Approved, Investigational
SunitinibDeslanoside may decrease the cardiotoxic activities of Sunitinib.Approved, Investigational
SuraminDeslanoside may decrease the cardiotoxic activities of Suramin.Approved, Investigational
TalaporfinDeslanoside may decrease the cardiotoxic activities of Talaporfin.Investigational
TalazoparibDeslanoside may decrease the cardiotoxic activities of Talazoparib.Investigational
TalinololTalinolol may increase the bradycardic activities of Deslanoside.Investigational
TamoxifenDeslanoside may decrease the cardiotoxic activities of Tamoxifen.Approved
TaselisibDeslanoside may decrease the cardiotoxic activities of Taselisib.Investigational
TaurolidineDeslanoside may decrease the cardiotoxic activities of Taurolidine.Investigational
TegafurDeslanoside may decrease the cardiotoxic activities of Tegafur.Approved
TelithromycinThe serum concentration of Deslanoside can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Deslanoside can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinDeslanoside may decrease the cardiotoxic activities of Temafloxacin.Withdrawn
TemoporfinDeslanoside may decrease the cardiotoxic activities of Temoporfin.Approved, Investigational
TemozolomideDeslanoside may decrease the cardiotoxic activities of Temozolomide.Approved, Investigational
TemsirolimusDeslanoside may decrease the cardiotoxic activities of Temsirolimus.Approved
TeniposideDeslanoside may decrease the cardiotoxic activities of Teniposide.Approved
TertatololTertatolol may increase the bradycardic activities of Deslanoside.Experimental
TestolactoneDeslanoside may decrease the cardiotoxic activities of Testolactone.Approved, Investigational
TezacitabineDeslanoside may decrease the cardiotoxic activities of Tezacitabine.Investigational
ThalidomideDeslanoside may decrease the cardiotoxic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiotepaDeslanoside may decrease the cardiotoxic activities of Thiotepa.Approved
ThymalfasinDeslanoside may decrease the cardiotoxic activities of Thymalfasin.Approved, Investigational
TiazofurineDeslanoside may decrease the cardiotoxic activities of Tiazofurine.Experimental
TiboloneDeslanoside may decrease the cardiotoxic activities of Tibolone.Approved, Investigational
TimololTimolol may increase the bradycardic activities of Deslanoside.Approved
TioguanineDeslanoside may decrease the cardiotoxic activities of Tioguanine.Approved
Tiomolibdate ionDeslanoside may decrease the cardiotoxic activities of Tiomolibdate ion.Investigational
TipifarnibDeslanoside may decrease the cardiotoxic activities of Tipifarnib.Investigational
TirapazamineDeslanoside may decrease the cardiotoxic activities of Tirapazamine.Investigational
TivozanibDeslanoside may decrease the cardiotoxic activities of Tivozanib.Investigational
TobramycinThe serum concentration of Deslanoside can be decreased when it is combined with Tobramycin.Approved, Investigational
TolevamerThe risk or severity of adverse effects can be increased when Tolevamer is combined with Deslanoside.Approved
TopotecanDeslanoside may decrease the cardiotoxic activities of Topotecan.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.Approved
ToremifeneDeslanoside may decrease the cardiotoxic activities of Toremifene.Approved, Investigational
TositumomabDeslanoside may decrease the cardiotoxic activities of Tositumomab.Approved, Investigational
ToyocamycinDeslanoside may decrease the cardiotoxic activities of Toyocamycin.Experimental
TrabectedinDeslanoside may decrease the cardiotoxic activities of Trabectedin.Approved, Investigational
TrametinibDeslanoside may decrease the cardiotoxic activities of Trametinib.Approved
TrastuzumabDeslanoside may decrease the cardiotoxic activities of Trastuzumab.Approved, Investigational
Trastuzumab emtansineDeslanoside may decrease the cardiotoxic activities of Trastuzumab emtansine.Approved
TrebananibDeslanoside may decrease the cardiotoxic activities of Trebananib.Investigational
TremelimumabDeslanoside may decrease the cardiotoxic activities of Tremelimumab.Investigational
TreosulfanDeslanoside may decrease the cardiotoxic activities of Treosulfan.Investigational
TretazicarDeslanoside may decrease the cardiotoxic activities of Tretazicar.Investigational
TretinoinDeslanoside may decrease the cardiotoxic activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe therapeutic efficacy of Deslanoside can be decreased when used in combination with Triamterene.Approved
TriaziquoneDeslanoside may decrease the cardiotoxic activities of Triaziquone.Experimental
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside.Approved, Vet Approved
TrifluridineDeslanoside may decrease the cardiotoxic activities of Trifluridine.Approved
TrilostaneDeslanoside may decrease the cardiotoxic activities of Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimetrexateDeslanoside may decrease the cardiotoxic activities of Trimetrexate.Approved, Investigational
TriptolideDeslanoside may decrease the cardiotoxic activities of Triptolide.Investigational
TriptorelinDeslanoside may decrease the cardiotoxic activities of Triptorelin.Approved, Vet Approved
TrofosfamideDeslanoside may decrease the cardiotoxic activities of Trofosfamide.Investigational
TrovafloxacinDeslanoside may decrease the cardiotoxic activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxacitabineDeslanoside may decrease the cardiotoxic activities of Troxacitabine.Investigational
TubercidinDeslanoside may decrease the cardiotoxic activities of Tubercidin.Experimental
TubocurarineTubocurarine may increase the arrhythmogenic activities of Deslanoside.Approved
TylosinThe serum concentration of Deslanoside can be increased when it is combined with Tylosin.Vet Approved
UbenimexDeslanoside may decrease the cardiotoxic activities of Ubenimex.Experimental, Investigational
Uracil mustardDeslanoside may decrease the cardiotoxic activities of Uracil mustard.Approved
VadimezanDeslanoside may decrease the cardiotoxic activities of Vadimezan.Investigational
ValrubicinDeslanoside may decrease the cardiotoxic activities of Valrubicin.Approved
VandetanibDeslanoside may decrease the cardiotoxic activities of Vandetanib.Approved
VapreotideDeslanoside may decrease the cardiotoxic activities of Vapreotide.Approved, Investigational
VecuroniumVecuronium may increase the arrhythmogenic activities of Deslanoside.Approved
VeliparibDeslanoside may decrease the cardiotoxic activities of Veliparib.Investigational
VemurafenibDeslanoside may decrease the cardiotoxic activities of Vemurafenib.Approved
VenetoclaxDeslanoside may decrease the cardiotoxic activities of Venetoclax.Approved
VerapamilVerapamil may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
VerteporfinDeslanoside may decrease the cardiotoxic activities of Verteporfin.Approved, Investigational
VesnarinoneDeslanoside may decrease the cardiotoxic activities of Vesnarinone.Investigational
VinblastineDeslanoside may decrease the cardiotoxic activities of Vinblastine.Approved
VincristineDeslanoside may decrease the cardiotoxic activities of Vincristine.Approved, Investigational
VindesineDeslanoside may decrease the cardiotoxic activities of Vindesine.Approved, Investigational
VinflunineDeslanoside may decrease the cardiotoxic activities of Vinflunine.Approved
VinorelbineDeslanoside may decrease the cardiotoxic activities of Vinorelbine.Approved, Investigational
VintafolideDeslanoside may decrease the cardiotoxic activities of Vintafolide.Investigational
VismodegibDeslanoside may decrease the cardiotoxic activities of Vismodegib.Approved
Vitamin ADeslanoside may decrease the cardiotoxic activities of Vitamin A.Approved, Nutraceutical, Vet Approved
VorinostatDeslanoside may decrease the cardiotoxic activities of Vorinostat.Approved, Investigational
VorozoleDeslanoside may decrease the cardiotoxic activities of Vorozole.Experimental
Zoptarelin doxorubicinThe serum concentration of Deslanoside can be decreased when it is combined with Zoptarelin doxorubicin.Investigational
ZorubicinDeslanoside may decrease the cardiotoxic activities of Zorubicin.Experimental
Zuretinol acetateDeslanoside may decrease the cardiotoxic activities of Zuretinol acetate.Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15211
KEGG Drug
D01240
PubChem Compound
28620
PubChem Substance
46507176
ChemSpider
26618
ChEBI
31468
ChEMBL
CHEMBL1614
Therapeutic Targets Database
DAP000464
PharmGKB
PA164747478
Wikipedia
Deslanoside
ATC Codes
C01AA07 — Deslanoside

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP0.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.468 mg/mLALOGPS
logP-0.49ALOGPS
logP0.6ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)7.15ChemAxon
pKa (Strongest Basic)-3.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count9ChemAxon
Polar Surface Area282.21 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity225.65 m3·mol-1ChemAxon
Polarizability100.65 Å3ChemAxon
Number of Rings9ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8985
Blood Brain Barrier-0.5781
Caco-2 permeable-0.924
P-glycoprotein substrateSubstrate0.8738
P-glycoprotein inhibitor IInhibitor0.5533
P-glycoprotein inhibitor IIInhibitor0.6189
Renal organic cation transporterNon-inhibitor0.8371
CYP450 2C9 substrateNon-substrate0.8483
CYP450 2D6 substrateNon-substrate0.8905
CYP450 3A4 substrateSubstrate0.7052
CYP450 1A2 substrateNon-inhibitor0.9197
CYP450 2C9 inhibitorNon-inhibitor0.9182
CYP450 2D6 inhibitorNon-inhibitor0.938
CYP450 2C19 inhibitorNon-inhibitor0.9284
CYP450 3A4 inhibitorNon-inhibitor0.9194
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9237
Ames testNon AMES toxic0.9309
CarcinogenicityNon-carcinogens0.9583
BiodegradationNot ready biodegradable0.9845
Rat acute toxicity4.9815 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9515
hERG inhibition (predictor II)Inhibitor0.8395
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Cardenolide glycosides and derivatives
Alternative Parents
Steroidal glycosides / Oligosaccharides / 12-hydroxysteroids / 14-hydroxysteroids / O-glycosyl compounds / Butenolides / Oxanes / Tertiary alcohols / Enoate esters / Secondary alcohols
show 10 more
Substituents
Cardanolide-glycoside / Steroidal glycoside / Oligosaccharide / 12-hydroxysteroid / 14-hydroxysteroid / Hydroxysteroid / Glycosyl compound / O-glycosyl compound / 2-furanone / Oxane
show 22 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
tetrasaccharide derivative, 14beta-hydroxy steroid, cardenolide glycoside, 12beta-hydroxy steroid (CHEBI:31468)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Zhao YN, Pan Y, Tao JL, Xing DM, Du LJ: Study on cardioactive effects of brazilein. Pharmacology. 2006;76(2):76-83. Epub 2005 Nov 24. [PubMed:16319518]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:46